PrimeVigilance is pleased to announce that both Dr. Michael Forstner (PrimeVigilance Senior VP – Head of Risk Management and Pharmacoepidemiology) and Dr Jan Petracek (PrimeVigilance CEO, and former Head of Risk Management at EMA) were selected expert speakers during the upcoming DIA Pharmacovigilance and Risk Management Strategies Conference held this January 28-30, 2019 in Washington, DC.
13 December 2018.
London, UK – 28 November 2018: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, is delighted to have been shortlisted for the Best Technological Development in Clinical Trials category at the 14th Annual SCRIP Awards
28 November 2018.
Guildford, UK – 24th October 2018
PrimeVigilance have become WORLDWIDE NUMBER ONE in QPPV services with 25 EU QPPV assignments, as well as 25 Deputy EU QPPVs, and our local QPPV/NPRP network covering over 60 countries !
24 October 2018.
We are pleased to share the news that Dr Jan Petracek, PrimeVigilance CEO and a leading expert in Pharmacovigilance, will be lecturing at the upcoming MHRA/DIA Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing course held in London on Oct 15 – 19, 2018.
14 September 2018.
PrimeVigilance has added specialist pharmacoepidemiology and risk management services, offering best in class systematic approaches to lifecycle benefit-risk management profile optimization.
22 August 2018.
PrimeVigilance is pleased to share the news that Philippe Sorel, our Associate Director of Global Medical Information, has been invited to speak twice during the DIA Global Annual Meeting taking place on June 24-28, 2018, in Boston USA.
13 June 2018.
+44 (0)1483 307920
(+1) 781 703 5540
United Kingdom (Head Office)